Nathan W. Luedtke
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nathan W. Luedtke.
Journal of Biological Chemistry | 2000
Assaf Friedler; Dorit Friedler; Nathan W. Luedtke; Yitzhak Tor; Abraham Loyter; Chaim Gilon
We have used the backbone cyclic proteinomimetics approach to develop peptides that functionally mimic the arginine-rich motif (ARM) of the HIV-1 Tat protein. This consensus sequence serves both as a nuclear localization signal (NLS) and as an RNA binding domain. Based on the NMR structure of Tat, we have designed and synthesized a backbone cyclic ARM mimetic peptide library. The peptides were screened for their ability to mediate nuclear import of the corresponding BSA conjugates in permeabilized cells. One peptide, designated “Tat11,” displayed active NLS properties. Nuclear import of Tat11-BSA was found to proceed by the same distinct pathway used by the Tat-NLS and not by the common importin α pathway, which is used by the SV40-NLS. Most of the Tat-derived backbone cyclic peptides display selective inhibitory activity as demonstrated by the inhibition of the nuclear import mediated by the Tat-NLS and not by the SV40-NLS. The Tat-ARM-derived peptides, including Tat-11, also inhibited binding of the HIV-1 Rev-ARM to its corresponding RNA element (Rev response element) with inhibition constants of 5 nm. Here we have shown for the first time (a) a functional mimetic of a protein sequence, which activates a nuclear import receptor and (b) a mimetic of a protein sequence with a dual functionality. Tat11 is a lead compound which can potentially inhibit the HIV-1 life cycle by a dual mechanism: inhibition of nuclear import and of RNA binding.
Bioorganic & Medicinal Chemistry | 2001
Sarah R. Kirk; Nathan W. Luedtke; Yitzhak Tor
The design, synthesis and study of internally fluorescent hammerhead (HH) ribozymes, where changes in fluorescence parameters directly reflect the progress of the ribozymes cleavage chemistry, are described. The approach relies on a HH substrate modified at position 1.1, proximal to the cleavage site, with 2-aminopurine (2AP), an intensely fluorescent adenosine isoster. The incorporation of 2AP, an unnatural nucleoside, does not interfere with the ribozyme folding and catalysis. Since 2AP is highly sensitive to environmental changes, its fluorescence is dramatically altered upon ribozyme-mediated cleavage of the substrate. This generates a measurable signal that directly reflects the progress of the ribozymes reaction in real time. Identical pseudo first order rate constants are obtained for HH constructs using both continuous fluorescence monitoring and radioactive labeling. This rapid and real-time monitoring facilitates the study of ribozyme activity under different conditions (e.g., ionic strength, pH, etc.), and provides a useful assay to rapidly screen potential inhibitors. Three hitherto unknown HH inhibitors are presented and compared to neomycin B and chlortetracycline, two previously studied HH inhibitors. All three new small molecules, neo-acridine, guanidino-neomycin B, and [Delta-(Eilatin)Ru(bpy)(2)](2+), prove to be better inhibitors than neomycin B or chlortetracycline. Investigating HH inhibition under different ionic strengths reveals that the binding of neo-acridine, [Delta-(Eilatin)Ru(bpy)(2)](2+), and chlortetracycline to the HH involves hydrophobic interactions as their RNA affinities are largely unaffected by increasing salt concentrations. In contrast, neomycin B loses more than 50-fold of its inhibitory ability as the NaCl concentration is increased from 50 to 500mM.
ChemBioChem | 2002
Nathan W. Luedtke; Judy S. Hwang; Edith C. Glazer; Dalia Gut; Moshe Kol; Yitzhak Tor
Eilatin‐containing octahedral ruthenium complexes inhibit HIV‐1 replication in CD4+ HeLa cells and in human peripheral blood monocytes with IC50 values of approximately 1 μM. Similar metal complexes that lack eilatin display 15–100‐fold lower anti‐HIV activities. [Ru(bpy)2“pre‐eilatin”]2+, a complex that contains a nonplanar analogue of eilatin, shows significantly lower nucleic acid binding and lower anti‐HIV activity than eilatin complexes. This result indicates that the extended planar surface presented by eilatin is important for both activities. Rev peptide and ethidium bromide displacement assays are used to probe the nucleic acid affinity and specificity of Λ‐ and Δ‐[Ru(bpy)2eilatin]2+. Two HIV‐1 RNA sites are compared and a significant binding preference for the Rev response element over the transactivation response region is found. Simple DNA duplexes show a consistent selectivity for Λ‐[Ru(bpy)2eilatin]2+ compared to Δ‐[Ru(bpy)2eilatin]2+, while RNAs show more diverse enantiomeric selectivities.
Tetrahedron Letters | 2001
Qi Liu; Nathan W. Luedtke; Yitzhak Tor
Abstract A versatile and highly efficient synthesis of monosubstituted ureas is described. The reaction of an amine with 4-nitrophenyl-N-benzylcarbamate, followed by hydrogenolysis, provides the corresponding urea in high yield and purity. This carbamate can also be employed for the derivatization of water-soluble polyamines (e.g. aminoglycoside antibiotics), while other reagents (e.g. benzylisocyanate) fail to give the desired products in any significant yield.
Biopolymers | 2003
Nathan W. Luedtke; Yitzhak Tor
Chemistry: A European Journal | 2005
Nathan W. Luedtke; Qi Liu; Yitzhak Tor
Angewandte Chemie | 2005
Jürgen Boer; Kenneth F. Blount; Nathan W. Luedtke; Lev Elson-Schwab; Yitzhak Tor
Bioorganic & Medicinal Chemistry | 2003
Nathan W. Luedtke; Qi Liu; Yitzhak Tor
Angewandte Chemie | 2000
Nathan W. Luedtke; Yitzhak Tor
Chemical Communications | 2004
Janice R. Aldrich-Wright; Craig R. Brodie; Edith C. Glazer; Nathan W. Luedtke; Lev Elson-Schwab; Yitzhak Tor